Natera's Q1 2017 Revenues Drop 24 Percent

May 09, 2017

NEW YORK (GenomeWeb) – Natera reported after the market on Tuesday that its first quarter 2017 revenues declined 24 percent over the first quarter 2016.

The San Carlos, California-based molecular diagnostics firm recognized $46.9 million in Q1 revenues, down from $61.9 million in Q1 2016. It beat analysts' average estimate of $42.8 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Featured White Papers

Best Practices for RNA Transcriptome Sequencing

Tissue Section Imaging

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Jul

19

Featured Webinar

Advances in NGS for Ultra-High Sensitivity Applications in Translational and Clinical Research

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.

Jul

24

Featured Webinar

Identifying Inherited Risk Factors of Pancreatic Cancer Using Targeted Sequencing in a Large Cohort

In this webinar, Dr. Fergus Couch from the Mayo Clinic will present data from a large study that used a targeted sequencing panel to determine pancreatic cancer risk associated with inherited mutations in several cancer predisposition genes.

Aug

09

Featured Webinar

Analytical Utility of Mass-Spec Liquid Biopsy for NSCLC and Melanoma Samples

In this two-part webinar, Dr. Elin Gray, from Edith Cowan University, and Ms. Weiwei Zhao, from Kingmed diagnostic, will compare the highly sensitive, multiplexed UltraSEEK technology, on the MassARRAY system, to digital droplet PCR (ddPCR) results on melanoma and non-small cell lung carcinoma samples.

Aug

14

Featured Webinar

From Panels to Exome – Assessing the Technical Performance of dsDNA Capture Probes for NGS Variant Detection

This webinar will explore advances in next-generation sequencing (NGS) library prep technologies and their relationship to the evolution of targeted gene panels.

Main menu